Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?
Date
2015-01-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
OXFORD UNIV PRESS
Abstract
This letter criticize the design of ACTS-CC trial
patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.
patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.